Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Frontier Ip Group Plc LSE:FIPP London Ordinary Share GB00B63PS212 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  1.50 1.39% 109.50 23,772 13:37:24
Bid Price Offer Price High Price Low Price Open Price
108.00 111.00 109.50 108.00 108.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.40 4.18 8.76 12.5 56
Last Trade Time Trade Type Trade Size Trade Price Currency
14:20:01 O 1,831 109.5001 GBX

Frontier Ip (FIPP) Latest News

More Frontier Ip News
Frontier Ip Investors    Frontier Ip Takeover Rumours

Frontier Ip (FIPP) Discussions and Chat

Frontier Ip Forums and Chat

Date Time Title Posts
08/6/202120:07Frontier IP184
30/7/201123:11Why have they bothered1

Add a New Thread

Frontier Ip (FIPP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-23 13:20:02109.501,8312,004.95O
2021-06-23 13:10:05111.00890987.90O
2021-06-23 13:07:26111.00900999.00O
2021-06-23 13:00:29110.00675742.50UT
2021-06-23 12:49:07109.505,0005,475.01O
View all Frontier Ip trades in real-time

Frontier Ip (FIPP) Top Chat Posts

DateSubject
23/6/2021
09:20
Frontier Ip Daily Update: Frontier Ip Group Plc is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker FIPP. The last closing price for Frontier Ip was 108p.
Frontier Ip Group Plc has a 4 week average price of 87.50p and a 12 week average price of 71p.
The 1 year high share price is 115p while the 1 year low share price is currently 58p.
There are currently 50,762,406 shares in issue and the average daily traded volume is 42,467 shares. The market capitalisation of Frontier Ip Group Plc is £55,584,834.57.
28/5/2021
14:20
b3rt1e: Zac Mir podcast on Vox has predicted from the FIPP chart that the share price is heading to 110p by end June
28/4/2021
19:42
gersemi: Tipped by ST in the IC - -- Frontier IP’s hidden value Exscientia latest fundraise at material premium to carrying value of Frontier’s holding. Annual results to be “be materially ahead of management expectations”. Shares in Frontier IP (FIPP:83p), a company that provides a range of commercialisation services to university spin-outs in return for ‘free equity’ stakes, have increased 40 per cent in value since I highlighted the company’s ‘hidden value’ (‘Exploiting two small-cap pricing anomalies’, 5 March 2021). The re-rating is far from over. That’s because Frontier’s largest portfolio company, Exscientia, a clinical stage pharma technology company pioneering the use of artificial intelligence (AI) to design new drugs, has just raised US$225m (£162m) in a Series D funding round led by Softbank’s Vision fund. It was backed by a host of shrewd investors including GT Healthcare Capital and Bristol-Myers Squibb. In addition, Softbank is providing an additional US$300m equity commitment to Exscientia that can be drawn at its discretion. Exscientia has advanced the first two fully AI-designed drugs into clinical trials and now has over 20 active programs in its pipeline Frontier’s 2.27 per cent stake in Exscientia was revalued up by £1.87m to £6.269m (11.4p a share) at 31 December 2020, implying a read through valuation of £276m ($384m). However, Sky News subsequently reported Exscientia’s March 2021 $100m Series C investment round managed by BlackRock was priced at a $650m (£464m) valuation, implying a £9.8m (17.8p a share) valuation for Frontier's 2.11 per cent diluted stake. Although Exscientia has yet to reveal valuation details of this week’s US$225m Series D funding round, Frontier’s corporate broker N+1 Singer expects the company to deliver £6m valuation gains in the second half to June 2021 and has a £61m (111p a share) sum-of-the-parts valuation on the portfolio. My 100p target price could prove conservative. Buy.
28/4/2021
12:36
acuere: Exscientia was the main reason I bought into Fipp.It’s not clear what our percentage stake in Exscientia will now be after this latest funding round. However even if we are down to 1%, I still believe that stake could be worth more than the current market cap of Fipp. A couple of years ago it was thought Exscientia would list on Nasdaq with $1bn valuation. I suspect that if and when they do decide to go down that route it will attract a valuation a few multiples of that.
28/4/2021
11:10
tizo100: PE 9.25PEG Factor only 0.18On yesterday's closing priceWell and truly undervalued dyor I'm adding on any weakness.
19/3/2021
09:02
tizo100: Glad I jumped aboard where do you see the price in 1-2 years
12/3/2021
07:08
tizo100: Octopus Investments increasing their holdings. Nice! hTTps://uk.advfn.com/stock-market/london/frontier-ip-FIPP/share-news/Frontier-IP-Group-plc-Holdings-in-Company/84561902
10/3/2021
12:13
tizo100: I have also been running my slide rule over Frontier IP (FIPP), a company that provides commercialisation services to university spin-outs in return for ‘free equity’ stakes. The online-article is worth a read ahead of likely valuation uplifts in this month’s interim results. Frontier IP commercialising valuable technology Exscentia and Pulsiv’s fundraises at premium to carrying value of Frontier’s holdings. The Vaccine Group has undertaken animal trials with three vaccine candidates. Investors are underestimating the potential for valuation uplifts from Frontier IP (FIPP:60p), a company that provides a range of commercialisation services to university spin-outs in return for ‘free equity’ stakes. For starters, portfolio company Pulsiv Solar has recently raised £890,000 in new money through an equity fundraising to accelerate development and scale up of its technology which improves energy efficiency of power converters used in a wide range of everyday products. The fundraise and debt conversion values Pulsiv at £21.8m, with Frontier IP's resulting 18.8 per cent equity stake now worth £4.1m (8.1p a share). The investment was held at £3.6m (7.1p a share) in Frontier’s last annual accounts at 30 June 2020, representing 13.9 per cent of the company’s NAV of £25.9m (51p a share). Furthermore, Pulsiv, a spin out from the University of Plymouth, has been working with a major multinational to incorporate its technology into a new consumer product line. It has also been working with German engineering giant Bosch to optimise design of an energy-efficient solar microinverter prototype to prepare it for mass manufacture. Frontier’s largest portfolio company, Exscientia, a clinical stage pharma technology company that is pioneering the use of artificial intelligence (AI) to design new drugs, has just completed a US$100m Series C financing round. In May 2020, Exscientia raised $60m from investors including Bristol-Myers Squibb, Novo Holdings, Evotec and GT Healthcare Capital. Funds managed by BlackRock have just joined the investment round. The capital will be used to support Exscientia's platform development towards autonomous drug design and expand existing capabilities in biological analytics that support target selection and portfolio development. Exscientia’s end-to-end AI-first drug discovery platform, CentaurAI™, is enabling the company to generate novel drugs and overcome conventional drug discovery limitations several years faster than industry benchmarks. Exscientia has demonstrated the platform's capabilities by creating the first fully AI-designed drug to enter clinical trials and advancing multiple drug candidates into preclinical testing. In addition to its growing proprietary pipeline, the company has conducted drug discovery partnerships with Bristol-Myers Squibb, Sanofi, Bayer and Dainippon Sumitomo as well as several biotech companies. Frontier’s 2.4 per cent stake in Exscientia was valued at £4.4m (8.7p a share) at 30 June 2020, implying a read through valuation for the company of £183.3m ($256m). Following Exscientia’s fundraise this week, Frontier now holds 2.11 per cent equity but is set to book a hefty uplift on the value of its holding. Although the terms of BlackRock's funding are yet to disclosed, Sky News is reporting from sources that the investment round was priced at a $650m (£464m) valuation. On this basis, Frontier's stake in Exscientia could now be worth £9.8m (19.4p a share). Covid-19 winner: Robotic technology in harvesting Frontier’s other portfolio companies are performing well, too. Fieldwork Robotics, a developer of robotic technology to harvest soft fruit and vegetables that addresses the need for heightened food safety and the shortage of UK seasonal workers, is progressing with a raspberry-harvesting robot in collaboration with Hall Hunter Partnership, one of the UK's biggest soft fruit producers, and is working with Bosch to optimise the software and design of the robotic arms. An alpha prototype for manufacturability of its raspberry harvesting robot is expected for trials later this year. Fieldwork is also developing a cauliflower harvesting robot with Bonduelle, a leading vegetable producer in more than 100 countries. Frontier IP holds a 26.7 per cent stake worth £1.35m. A novel approach to fighting Sars-Cov-2 in animals One of the most exciting investments is Frontier’s 17 per cent stake (book value of £3m) in The Vaccine Group (TVG), a company that is developing vaccines initially for use in animals to tackle Sars-Cov-2, the virus causing Covid-19. As most diseases that afflict humans originally arise in other animals, it is sensible to tackle them at source. Moreover, there is considerable value in developing animal vaccines because of the economic damage diseases, such as bovine tuberculosis, can cause. For instance, Sars-Cov-2 originally arose in bats and entered human populations via an unidentified intermediary species. Covid-19 has also been found in cats, dogs, ferrets and mink. Longer term, there is potential for TVG to develop a vaccine for use in humans. Indeed, Oxford University says there will be a need for second-generation vaccines because of the danger from virus mutations reducing the efficacy of those currently being deployed. TVG’s technology takes a different approach to attacking the virus than other vaccines under development. The science is worth explaining as it highlights the blue-sky potential for TVG, and the upside for Frontier IP. Sars-Cov-2 infects people via its spike proteins which latch on to a protein, ACE 2, found on cells in alveoli and other parts of the body. The alveoli are where the lungs and blood exchange oxygen from the air and carbon dioxide in the process of breathing in and out. The spike protein forces an entry into a cell by cracking it open using the interaction with the ACE 2 protein. It is estimated there are more than 180 Sars-Cov-2 vaccines under development. Most are targeting the spike proteins: they aim to train the body’s natural defences to recognise the spike protein and destroy the virus in the body. The concerns around the emergence of the Kent, Brazil and South African Sars-Cov-2 variants, all resulting from spike protein mutations, highlight two major issues: Firstly, the spike protein mutates more often than other proteins in the virus, perhaps because it is the contact point between the virus and host. Secondly, because it is the main contact point between the virus and host, mutations able to avoid or overcome the body’s defences mean a variant virus is likely to gain ground more rapidly. Bearing this in mind, TVG’s vaccine candidates are targeting the nucleocapsid and membrane proteins, both essential to the virus’s structure. These proteins are building blocks necessary for constructing the virus’s core and surface, and are created earlier than spike proteins as the virus reproduces itself — meaning a vaccine that targets them can eradicate the virus sooner. TVG has undertaken initial animal trials with three of the six current vaccine candidates and is analysing the data from these trials, with the other three about to be tested. The company is also making good progress with animal vaccines for Ebola, Lassa fever and other diseases causing human or economic harm, including bovine tuberculosis. Frontier’s 17 per cent stake in TVG was last valued at £3m, a conservative valuation if the company succeeds with its government funded vaccine programmes. I first suggested buying Frontier’s shares at 56p (Alpha Research: ‘A differentiated IP play’, 15 Nov 2019), and they still only trade on a modest premium to last reported NAV even though forthcoming interim results on Wednesday, 24 March 2020 should deliver valuation uplifts from several investee companies. Buy.
10/3/2021
12:07
tizo100: After missing the boat on Monday and after doing extensive research prior to this I have decided to invest today after the small pullback. Should see it rise in the run up to results, looks to have tremendous potential. Got in below the mid price as well. Good luck all
08/3/2021
13:03
gordan ghetto: ANA is the best UK cannabis stock Share price 1.1p Only £6.4m mkt cap Fastest growing sector worldwide Will have first mover advantage in UK Same growers as GW Pharma 4 biggest shareholders hold over 50% BOD own 30% Massively undervalued (£6.4m mkt cap) Near term multi bagger on license approval Partners with leading prof , scientists etc Primed for a RTO/ main listing (price driver) Under the radar (most chased MXC,CBX) Looking to bring a product to market Off take agreement in place already Will be producing 200 TONS per year (200,000 kilos) Has the most land out of every cannabis co Fully funded for phase 1 UK medical cannabis growing 20% month Only 584m shares in issue Hardly any available in open market Will apply for a commercial license too Worth getting in on the ground floor imho. hTTps://businesscann.com/work-on-12m-medicinal-cannabis-cultivation-facility-held-up-by-covid-19-uk-travel-ban/ hTTps://anandadevelopments.com/tiamat-agriculture-ltd/
23/6/2020
13:40
acuere: Fine progress being made in The Vaccine Group abounded today - in which FIPP hold 17%. “The overall progress made by TVG during the past year is likely to result in a material valuation uplift in the holding of TVG in the Group's audited results to 30 June 2020.” I think when investors fully digest the value and potential of Fipps holdings it’s difficult not to see the share price trading much neare a £1 in the ear future.
Frontier Ip share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
FIPP
Frontier I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210624 05:09:35